GLP-1 and Heart Disease: The SELECT Trial Changed Everything

In November 2023, the SELECT trial results were presented at the American Heart Association meeting and published simultaneously in the New England Journal of Medicine. The results were paradigm-shifting: semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% in overweight/obese adults with established cardiovascular disease — and crucially, without requiring a diabetes diagnosis. This single trial transformed GLP-1 medications from "weight loss drugs" into potentially the most important cardiovascular protective agents discovered in a generation.

If you have cardiovascular risk factors alongside excess weight, connect with Telehealth FX for a clinical evaluation. This article breaks down the SELECT trial design, the 20% MACE reduction, how this compares to statins, and the lipid benefits that accompany GLP-1 therapy.

The SELECT Trial: Study Design

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 adults aged 45+ with BMI ≥ 27, established cardiovascular disease (prior MI, stroke, or PAD), and no diabetes. Participants received semaglutide 2.4mg or placebo for a mean of 39.8 months. The primary endpoint was time to first MACE — cardiovascular death, nonfatal MI, or nonfatal stroke.

Why This Matters: Beyond Weight Loss

The critical insight from SELECT: the cardiovascular protection occurred before maximum weight loss was achieved and beyond what weight loss alone could explain. Mediation analyses showed that weight loss accounted for only ~25% of the MACE reduction. The remaining 75% came from direct cardiovascular effects:

• Anti-inflammatory: hs-CRP dropped 35%, reducing arterial inflammation and plaque instability. See our inflammation deep dive.
• Anti-atherosclerotic: GLP-1 receptors on endothelial cells reduce oxidative stress and improve vascular function.
• Blood pressure reduction: Mean 3.3 mmHg systolic BP reduction — modest but clinically significant.
• Lipid improvement: Triglycerides dropped 18%, LDL improved, HDL increased.

How SELECT Compares to Statin Trials

The 20% MACE reduction from semaglutide is comparable to what statins achieved in their landmark trials (JUPITER showed 44% relative risk reduction, but in a higher-risk population). What makes SELECT unique is that it achieved cardiovascular protection through a completely different mechanism — metabolic and inflammatory improvement rather than cholesterol lowering — suggesting that GLP-1 therapy is additive to statin therapy, not redundant.

For patients already on a statin, adding semaglutide provides an additional layer of cardiovascular protection. The combination of diabetes prevention, weight loss, inflammation reduction, and cardiovascular protection makes GLP-1 therapy arguably the most impactful single medication intervention available for cardiometabolic risk.

Frequently Asked Questions

Do I need to have heart disease to benefit from the cardiovascular protection?

SELECT enrolled patients with established cardiovascular disease. The results are most directly applicable to secondary prevention. However, the anti-inflammatory and metabolic benefits likely confer some primary prevention benefit as well — this is being studied in ongoing trials.

Does tirzepatide also protect the heart?

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is still underway. Given its superior weight loss and anti-inflammatory effects, many cardiologists expect similar or better results. However, we do not have the data yet. Semaglutide is the only GLP-1 with proven cardiovascular outcomes data in non-diabetic patients.

Should I stop my statin if I start semaglutide?

Absolutely not. Semaglutide and statins work through complementary mechanisms. Continue all prescribed cardiovascular medications. GLP-1 therapy is additive, not a replacement.